FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Bryant Steven R.

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/10/2009 

3. Issuer Name and Ticker or Trading Symbol

ANGIOTECH PHARMACEUTICALS INC [ANPI]

(Last)        (First)        (Middle)

1618 STATION STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
SVP, Specialty Medical Device /

(Street)

VANCOUVER, A1 V6A 1B6       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option w/Tandem SARs   3/1/2007   (1) 2/4/2012   Common Stock   15000   (2) $7.65   D    
Stock Option w/Tandem SARs   12/1/2008   (3) 11/10/2013   Common Stock   25000   (2) $0.26   D    
Stock Option w/Tandem SARs   4/1/2009   (4) 3/9/2014   Common Stock   20000   (2) $0.27   D    
Stock Option w/Tandem SARs   4/1/2009   (4) 3/9/2014   Common Stock   2000   (2) $0.27   D    

Explanation of Responses:
( 1)  The options started to vest effective 03/01/2007 in equal installments on a monthly basis until 02/01/2011.
( 2)  Represents the number of the Company's common shares into which the stock options are convertible. In the event that the Reporting Person elects to exercise the tandem SAR, the stock option will be cancelled and the Reporting Person will be entitled to receive a number of common shares with an aggregate value equal to the product of (a) the excess of the market price of a common share on the date of the exercise over the exercise price of the tandem SAR, multiplied by (b) the number of the tandem SARs exercised.
( 3)  The options started to vest effective 12/01/2008 in equal installments on a monthly basis until 11/01/2012.
( 4)  The options will start to vest effective 04/01/2009 in equal installments on a monthly basis until 03/01/2013.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Bryant Steven R.
1618 STATION STREET
VANCOUVER, A1 V6A 1B6

SVP, Specialty Medical Device

Signatures
/s/David McMasters, Attorney-in-Fact 6/19/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.